Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1864663 (
HCC
)
2,985
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
USP22
, a member of the deubiquitinases (DUBs) family, is known to be a key subunit of the human Spt-Ada-Gcn5 acetyltransferase (hSAGA) transcriptional cofactor complex. Within hSAGA,
USP22
removes ubiquitin from histone proteins, thus regulating the transcription and expression of downstream genes.
USP22
plays important roles in many cancers; however, its effect and the mechanism underlying
HCC
chemoresistance remain unclear. In the present study, we found that
USP22
was highly expressed in chemoresistant
HCC
tissues and cells and was correlated with the prognosis of
HCC
patients who received chemotherapy. Silencing
USP22
in chemoresistant
HCC
Bel/Fu cells dramatically inhibited proliferation, migration, invasion and epithelial-mesenchymal transition in vitro; suppressed tumorigenic and metastatic capacities in vivo; and inhibited drug resistance-related proteins (MDR1, LRP, MRP1). Mechanistically, we found that
USP22
knockdown exerts its function through down-regulating PI3K and activating Smad4, which inhibited phosphorylation of Akt. Silencing Smad4 blocked
USP22
knockdown-induced Akt inhibition in Bel/Fu cells. Our results, for the first time, provide evidence that
USP22
plays a critical role in the development of chemoresistant
HCC
cells and that high
USP22
expression serves as a molecular marker for the prognosis of
HCC
patients who undergo chemotherapy.
...
PMID:USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt. 2844 68